FierceBiotech * FierceBiomarkers * FierceBiotechResearch * FierceBiotech * FierceBiotechIT * FierceCRO * FierceDiagnostics * FierceDrugDelivery * FierceMedicalDevices * FiercePharma * FiercePharmaManufacturing * FierceVaccines * More Fierce Network sites * Select another site * Advertise * Contact SEARCH______________ search Free Daily Biotech Industry Newsletter Get the latest on Biotech & Pharma Deals, Clinical Trials, FDA Decisions, and Key Regulatory Issues sent straight to your Inbox. Join over 100,000 biotech professionals who subscribe to FierceBiotech for FREE! Click here to see a sample. We never sell or give away your contact information. Our readers' trust comes first. [closer.png] EMAIL ADDRESS_______ SIGN ME UP FierceBiotech * NEWS * TOPICS + Biosimilars + Chutes and Ladders + Clinical Trials + Drug Safety + Emerging Markets + Europe + M&A + Outsourcing + Partnering + Personalized Medicine + Pipeline + R&D + Regulatory + Venture Capital * ANALYSIS + Download the FierceBiotech app for iPhone and iPad by Arsalan Arif + Public Citizen goes on a witch hunt at the FDA by John Carroll + John Reed sets out on a long-distance run at Roche's pRED by John Carroll + Fresh burst of biotech IPO pitches launches a busy Q4 season by John Carroll + VC funding follows tepid pace in Q3 as first-time biotech rounds shrivel by John Carroll + Industry Voices + More Commentary * FEATURES + The top 10 biotech IPOs of 2013 + 10 top drugs in biopharma's late-stage pipeline + Top 15 highest paid biopharma R&D chiefs + Top 10 generics makers by 2012 revenue + Top 10 Cardio Drugs 2012 + Top Med Tech Investments of Q3 + Top 15 Biotech VC Firms + Top 10 Pharma Companies by Employees + FierceMedicalDevices' 2013 Fierce 15 + Top 20 orphan drugs by 2018 * LIBRARY + Webinars + Whitepapers + eBooks + View All * EVENTS * JOBS + Browse Jobs + Post a Job * Marketplace * Subscribe * Twitter * Mobile Follow US Topics: Clinical Trials GlaxoSmithKline's Duchenne MD drug mirrors placebo effect in PhIII October 7, 2013 | By John Carroll Share Tools * Comment * Print * Contact Author * Reprint Over the weekend GlaxoSmithKline ($GSK) detailed the decisive failure of its ambitious Phase III study for drisapersen, a new drug designed to treat Duchenne muscular dystrophy. John Kraus, GSK's medical leader for drisapersen, unveiled more data from the failed study on the exon-skipping technology, which fell short not only on its primary endpoint for improved walking distances in a 6-minute test but also flunked out on three separate secondary endpoints, with the outcomes looking almost identical in each case with a placebo. After 48 weeks of therapy, says Kraus, the drisapersen group suffered a decline in walking distance, just as the placebo arm did. The decline was 10.3 meters in the drug arm's favor, falling short of a significant improvement and well off the more than 30-meter improvement seen in Phase II. Using the North Star Ambulatory Assessment test, the placebo arm scored 6.7 compared to a close 7.2 score for drisapersen. A velocity test gauging the time to climb four stairs was also virtually identical--a 0.12 decline in the placebo arm and a 0.14 decline in the drug group. There was a near mirror-image decline in the rate of patients' 10-meter walk/run velocity gauge. Kraus says the trial was well run and the quality outcomes they measured were good, providing a clear read out on the drug for the group they studied. Now investigators are going back over the data to see if a subset of patients benefited. And they are also running analyses on dystrophin expression to see how the therapy--in-licensed from the Dutch biotech Prosensa--influenced a key biomarker for the disease. "We need to understand if there may be a subpopulation that could have derived a benefit from drisapersen," Kraus tells FierceBiotech. "We are currently running analyses to help us understand." Subpopulation analysis is common in drug development, but it's far from ideal. A positive sign in a particular group might open the door to a new study geared for a narrow segment of the patient population, which has no meaningful therapy to rely on. But it's no guarantee of even limited success. Investors have been paying particularly close attention to the drisapersen data to see how it might reflect on eteplirsen, a DMD drug in development at Sarepta ($SRPT). Sarepta shares have soared on the positive outcome seen in a very small study of the drug, and the biotech believes it has a shot at an accelerated approval based on that study. Right now, eteplirsen is the leading therapy in the DMD field, and there's nothing in GlaxoSmithKline's latest data that changes any of that. Related Articles: Muscular dystrophy drug from GlaxoSmithKline, Prosensa fails PhIII New DMD data give Sarepta an edge in GlaxoSmithKline showdown Glaxo grabs coveted breakthrough drug status for muscular dystrophy drug Amid cheers and jeers, GlaxoSmithKline reveals Duchenne drug hit PhII goal Filed Under drisapersen, Duchenne muscular dystrophy, GlaxoSmithKline Comments View the discussion thread. Join 100,000+ Insiders SIGN UP FOR OUR NEWSLETTER EMAIL ADDRESS_______ SIGN ME UP FierceBiotech is the drug development industry's news monitor, covering biopharma deals, clinical trials, FDA decisions, and more. Subscribe to our free daily email and join the largest, most influential biotechnology news audience in the world. Sign up today! Popular Stories * Most Read * Most Shared * Is it human, animal or plant? At Bayer, they're mixing all three in new R&D recipe * U.S. domination of global biomedical R&D slips as Asian budgets swell * Merck R&D adopts its rivals' game plans in global overhaul * The 5 biggest trends in biopharma R&D in 2013 * FDA lifts a partial hold on Cell Therapeutics' leukemia drug * Flagship Ventures CEO keeps Merck aboard to inform biotech bets * [object Object] * [object Object] * Third Rock's Eleven pitches a $69M IPO to fuel its PhIII dry eye program * UPDATED: FDA spurns Sanofi's MS drug Lemtrada on fatally flawed PhIII design THE LIBRARY: WEBINAR Keys to Success for Your Integrated Summary of Safety (ISS) and Integrated Summary of Efficacy (ISE) | February 11, 1pm ET/ 10am PT | Sponsored by: Rho The integrated summary of safety (ISS) and the integrated summary of efficacy (ISE) are critical components of your new drug application (NDA) submission. This webinar will provide insights and important considerations for developing the ISS and ISE sections of your NDA. Register Today! MORE ITEMS Latest Commentary Merck R&D adopts its rivals' game plans in global overhaul The 5 biggest trends in biopharma R&D in 2013 Lundbeck stakes out a leading role for itself in late-stage Alzheimer's R&D Why did Roche kill off its Alzheimer's program for the BACE inhibitor RG7129? Meet the new publisher more EVENTS * Don't miss the First Clinical Event of 2014 - Exl's 3rd CROWN SummitJanuary 22-24 -- Philadelphia, PA * 6th Risk Evaluation and Mitigation Strategies Summit January 28-29 -- Alexandria, VA -- Westin Alexandria * Efficient Utilization of Maximo Asset Management within Life SciencesWednesday, January 8th -- 11am ET MORE EVENTS Press Releases * Johnson & Johnson Announces Quarterly Dividend for First Quarter 2014 * Lilly Sets Dates and Conference Calls for 2014 Financial Guidance and Fourth-Quarter 2013 Financial Results Announcements * Cancer Research UK and AstraZeneca sign deal to repurpose asthma drug that could fight kidney cancer * Advanced Cell Technology Appoints Eddy Anglade M.D. Executive Vice President of Clinical Development * Ocera Therapeutics Announces Election of Wendell Wierenga to Board * More Press Releases Featured Jobs * Quality Dossier Program Director - 13000004ZC Abbvie - Chicago IL United States * Senior Director, Global Knowledge & Strategic Intelligence Center Job Celgene Corporation - Berkeley Heights NJ US * Vice President, Global Medical Affairs - Breast Disease Lead Job Celgene Corporation - Summit NJ US * Sr. Director, Foreign Exchange (FX) Job Celgene Corporation - Berkeley Heights NJ US * Chief Financial Officer BioAgilytix Labs - Research Triangle Park NC USA A publication ofFierceMarkets FierceBiotech monitors biotech & pharma deals, FDA decisions, clinical trials, and more. Join more than 100,000 biotech industry leaders who subscribe to our free daily email. Click here to get your free weekly email briefing today! The FierceMarkets Network: Telecom * FierceCable * FierceDeveloper * FierceWireless:Europe * FierceWirelessTech * FierceOnlineVideo * FierceTelecom * FierceWireless Marketing & Retail * FierceCMO * FierceRetail * FierceMobileRetail * StorefrontBacktalk Healthcare * FierceEMR * FierceHealthcare * FierceHealthFinance * FierceHealthIT * FierceHealthPayer * FierceMedicalImaging * FierceMobileHealthcare * FiercePracticeManagement * Hospital Impact Government * FierceGovernment * FierceGovernmentIT * FierceHomelandSecurity * FierceMobileGovernment Energy * FierceEnergy * FierceSmartGrid Life Sciences * FierceBiomarkers * FierceBiotechResearch * FierceBiotech * FierceBiotechIT * FierceCRO * FierceDiagnostics * FierceDrugDelivery * FierceMedicalDevices * FiercePharma * FiercePharmaManufacturing * FierceVaccines Enterprise IT * FierceBigData * FierceCIO * FierceCIO:TechWatch * FierceContentManagement * FierceEnterpriseCommunications * FierceITSecurity * FierceMobileIT Finance * FierceCFO * FierceFinance * FierceFinanceIT * Home * Subscribe * Manage Newsletter Subscriptions * Advertise * Contact * Mobile Apps * RSS * Privacy * Editors * List in Marketplace (c) 2014 FierceMarkets. All rights reserved. Clicky